
Show Notes
Catatonia isn’t just mysterious, it’s one of the most treatable yet misunderstood syndromes in psychiatry.
In this episode, I continue my conversation with Dr. Mark Oldham, diving deep into what to actually do when you suspect catatonia. We talk through the Lorazepam challenge, what a “positive” response really means, and why sometimes a single dose can look like a miracle. We also dig into the gray zones—how to approach patients who don’t respond, when to move to ECT, and what to do when catatonia overlaps with delirium or psychosis.
Dr. Oldham shares his framework for identifying special cases, from benzodiazepine withdrawal to clozapine discontinuation, and explains why history-taking, not algorithms, is psychiatry’s most powerful diagnostic tool.
Takeaways:
Start simple, but think deeply. Lorazepam remains first-line for catatonia, but the absence of RCTs means clinical reasoning still leads the way.
ECT is definitive and underused. For refractory or malignant catatonia, ECT is often curative, but access and consent barriers remain a major challenge.
Not all catatonia is the same. Withdrawal states, chronic schizophrenia, and periodic catatonia each demand tailored interventions.
Delirium and catatonia can coexist. Treat both cautiously, start low, go slow, and always look for autoimmune or neurological causes.
History is your best guide. Behind every catatonic presentation is a story, missing it can mean missing the cure.
Selected references:
British Association for Psychopharmacology Guidelines
Rochester Catatonia Assessment Resources
NEJM Review on Catatonia
Nature Review on Catatonia
Schizophrenia Research Volume on Catatonia
Describing the Features of Catatonia (Oldham)
SUPPORT OUR PARTNERS:
SimplePractice.com/bootcamp (Now with AI documentation! Exclusive 7 day free trial and 50% off four months)
Beat the Boards Boot camp listeners now get FREE access to over 4400 exam-style questions)
Learn more and get transcripts for EVERY episode at https://www.psychiatrybootcamp.com/
For Sales Inquiries & Ad Rates, Please Contact:[email protected]
Connect with HumanContent on Socials: @humancontentpods
Produced by: Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Psychiatry Boot Camp
In this episode of Psychiatry Boot Camp, Dr. Mark Mullen continues his conversation with Dr. Jacob Appel, covering two intersecting frontiers. The replacement of human physicians by AI "replicants" and the emerging use of AI as a surrogate decision-maker, or "robo-proxy," for patients who lack decisional capacity. Dr. Appel argues that while AI will outperform human physicians in probabilistic, pattern-recognition tasks, it is structurally incapable of providing the authentic empathy, shared vulnerability, common sense, and irrational human trust that constitute the actual substance of healing and that deploying replicant physicians at scale will produce a deeply inequitable two-tiered healthcare system where wealthy patients see humans and less wealthy patients see machines.
In this episode of Psychiatry Bootcamp, Dr. Mark Mullen welcomes Dr. Jacob Appel, psychiatrist, attorney, bioethicist, polymath, and emergency psychiatrist, for a rigorous and clinically grounded critique of the Applebaum-Grisso "Four Abilities Model" of decisional capacity assessment. Dr. Appel traces the model's origins in the 1980s as a patient-empowerment tool, examines how its statutory adoption across more than half of US states has calcified it beyond its original intent, and describes in detail the categories of patients for whom the model systematically fails.
In this episode of Psychiatry Boot Camp recorded live at Saint Louis University, Dr. Mark Mullen is joined by Dr. Kristin Mueller, an emergency medicine physician and physician-researcher at Washington University in St. Louis, for a discussion on firearm violence as a public health crisis. Dr. Mueller, who works closely with the Life Outside of Violence hospital-based violence intervention program, walks through the clinical fundamentals of lethal means counseling, including a live mock counseling session demonstrating how to approach a patient in mental health crisis with access to firearms. The conversation covers practical, evidence-informed strategies for secure storage counseling, verbal de-escalation, and navigating patient resistance without leading with statistics alone.
Dr. Mark Mullen welcomes Dr. Allison Hadley, a psychiatrist and medical director of the psychiatric emergency service at Oregon Health & Science University, for a discussion on motivational interviewing in high-acuity psychiatric settings. Dr. Hadley introduces a novel teaching framework that draws on Tina Fey's rules of improv from her memoir Bossy Pants, mapping core improv principles, including "yes, and," making statements rather than only asking questions, and treating perceived mistakes as opportunities, onto the foundational techniques of motivational interviewing. The conversation covers the OARS mnemonic (open-ended questions, affirmations, reflections, and summaries), the relationship between motivational interviewing and trauma-informed care, and practical strategies for identifying and reinforcing patient change talk.
Dr. Mark Mullen welcomes Dr. Christine Crawford, Chief Medical Officer at the National Alliance on Mental Illness (NAMI) and author of You Are Not Alone: For Parents and Caregivers, alongside Steve Hoffmann, Senior Vice President and Chief Preclinical Officer at the Foundation for the National Institutes of Health (FNIH). Dr. Crawford discusses NAMI's mission and its 650 chapters nationwide, the concept of the "distress radius" as a framework for identifying when a child's behavioral changes warrant professional evaluation, and practical strategies for engaging skeptical patients and families through primary care. She also highlights dialectical behavioral therapy (DBT) as a broadly applicable clinical tool and underscores the importance of evidence-based education for patients and caregivers navigating the mental health system. The conversation then shifts to Steve Hoffmann's work at the FNIH, including the newly launching Multimodal Assessment and Phenotyping in Depression (MAPD) study, a longitudinal, multi-site initiative designed to identify biological, clinical, and digital biomarkers associated with depression subtypes. Hoffmann outlines the study's design, including neuroimaging, genetic testing, digital wearables, and patient-reported outcomes, with the goal of moving depression treatment away from a trial-and-error model toward a precision medicine approach. Dr. Crawford and Hoffmann both emphasize the importance of including patient voices in research design, drawing parallels to the foundational impact of the Alzheimer's Disease Neuroimaging Initiative (ADNI) on that field.